Rethinking Cardiovascular Events, End Points, and Surveillance in Oncology Trials
Cet article présente les recommandations de l'"American Heart Association" concernant la sélection systématique, la caractérisation rigoureuse et la validation des critères de jugement cardiovasculaires dans les essais en cancérologie
Advances in cancer therapeutics have transformed cancer into a curable or chronic disease for many patients. Consequently, long-term morbidity and competing risks have become increasingly relevant. Cardiovascular disease is the leading cause of non–cancer-related mortality among cancer survivors,1,2 prompting increased interest in the assessment of cardiovascular safety in oncology trials. The accompanying scientific statement, cosponsored by the American Heart Association and ASCO,3 calls for standardized definitions of cardiovascular adverse events, cardiovascular specialist involvement, and incorporation of cardiovascular end points in oncology clinical trials to promote better understanding of cancer therapy-related cardiac toxicities with the goal of improving outcomes for cancer survivors. However, translating these recommendations into practice requires careful consideration of both historical precedents and the unintended consequences of increased surveillance.
Journal of Clinical Oncology , éditorial en libre accès, 2026